Novo converts debt into Aradigm stake

Novo Nordisk has converted a $9.1 million debt into an equity stake in Aradigm. Novo gets 26 million shares at a price of 35 cents each. "Upon the closing of this transaction, we will have eliminated all debt from our balance sheet," said Aradigm CEO Igor Gonda. "We are appreciative of the support and cooperation we received from Novo Nordisk in executing this agreement." Report

Suggested Articles

The FDA has placed a phase 1/2 trial of Passage Bio’s GM1 gene therapy on clinical hold pending further assessment of the risk of its delivery device.

VBL got the green light after the committee looked at unblinded overall survival data for the second pre-planned interim analysis.

Eleusis researchers discovered that structural characteristics of the 2C-H class of psychedelics help to control asthma without behavioral effects.